Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

American Society of Clinical Oncology (ASCO) - Tập 27 Số 20 - Trang 3297-3302 - 2009
Sao Jiralerspong1, Shana L. Palla1, Sharon H. Giordano1, Funda Meric‐Bernstam1, Cornelia Liedtke1, Chad M. Barnett1, Limin Hsu1, Mien‐Chie Hung1, Gabriel N. Hortobágyi1, Ana María González-Angulo1
1From the Departments of Breast Medical Oncology, Biochemistry and Molecular Biology, Quantitative Sciences, Surgical Oncology, Pharmacy, Molecular and Cellular Oncology, and Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and the Department of Gynecology and Obstetrics, University of Muenster, Muenster, Germany.

Tóm tắt

Purpose Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in vitro and tumors in vivo. However, there is little clinical data to support this. Our purpose was to determine whether metformin use was associated with a change in pathologic complete response (pCR) rates in diabetic patients with breast cancer receiving neoadjuvant chemotherapy. Patients and Methods We identified 2,529 patients who received neoadjuvant chemotherapy for early-stage breast cancer between 1990 and 2007. Patients were compared by groups: 68 diabetic patients taking metformin, 87 diabetic patients not taking metformin, and 2,374 nondiabetic patients. pCR rates were compared between the three groups using χ2 tests of independence and compared pair- wise using a binomial test of proportions. Factors predictive of pCR were assessed using a multivariate logistic regression model. Results The rate of pCR was 24% in the metformin group, 8.0% in the nonmetformin group, and 16% in the nondiabetic group (P = .02). Pairwise comparisons between the metformin and nonmetformin groups (P = .007) and the nonmetformin and nondiabetic groups (P = .04) were significant. Comparison of the pCR rates between the metformin and nondiabetic groups trended toward but did not meet significance (P = .10). Metformin use was independently predictive of pCR (odds ratio, 2.95; P = .04) after adjustment for diabetes, body mass index, age, stage, grade, receptor status, and neoadjuvant taxane use. Conclusion Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving metformin. Additional studies to evaluate the potential of metformin as an antitumor agent are warranted.

Từ khóa


Tài liệu tham khảo

10.1200/JCO.2007.15.0235

Mieog JS, 2007, Cochrane Database Syst Rev, 2, CD005002

10.1016/S1470-2045(05)01736-5

10.1093/ajcn/86.3.823S

10.1002/ijc.22717

10.1001/jama.285.7.885

10.2337/diacare.26.4.1047

10.1093/aje/kwh161

10.1016/S0140-6736(08)60269-X

10.1111/j.1467-789X.2006.00261.x

10.1056/NEJMoa021423

10.1200/JCO.2007.14.7132

10.1038/nrc1408

10.1016/j.tem.2006.08.006

10.1038/nrc1387

10.1038/sj.bjc.6602963

10.1136/bmj.38415.708634.F7

10.2337/diacare.29.02.06.dc05-1558

10.1158/0008-5472.CAN-06-1500

10.1158/0008-5472.CAN-07-2310

10.1038/sj.onc.1211024

10.1158/0008-5472.CAN-06-4447

10.1042/BJ20080557

10.1016/j.exger.2005.07.007

10.1200/JCO.2005.02.6914

10.1517/13543784.15.9.1039

10.1038/nrm2327

Pollak MN, 2006, J Clin Oncol, 24, 9s, 10.1200/jco.2006.24.18_suppl.524

10.1200/JCO.2002.20.1.42

10.1002/ijc.21812

Goodwin PJ, 2006, Breast Cancer Res Treat, 100, S109, 10.1007/s10549-006-9230-z

10.1200/JCO.2007.12.7357

10.1093/jnci/djj494

10.1200/jco.2008.26.15_suppl.522

Fairey AS, 2003, Cancer Epidemiol Biomarkers Prev, 12, 721

10.1158/1055-9965.EPI-04-0736

10.1126/science.1120781

10.1101/gad.1199104

10.1016/S0092-8674(03)00929-2

10.1016/j.ccr.2004.06.007

10.1200/JCO.2007.15.3510

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 27 Số 20

3297-3302

Thông tin tác giả